Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$33.2MCash on Hand
22.3mo Cash Runway
Follow QNRX by emailGet an email when QNRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QNRX, unsubscribe in one click. Privacy
📣 What QNRX Says Is Next
the end of 2026 · QRX003: “The planned Phase 2/3 study in PSS, the first-ever company-sponsored formal clinical study for the disease, is expected to enroll up to 12 pediatric and adult patients in the United States and Europe and to initiate before the end of 2026.”
Company press release, Nov 6, 2026 · SEC filing
by the end of 2026 · “Quoin expects to complete recruitment of all 20 participants by the end of 2026 and to report topline data in the second quarter of 2027.”
Company press release, Nov 6, 2026 · SEC filing
year end · “We also plan to initiate the first-ever formal clinical study in Peeling Skin Syndrome before year end whilst simultaneously advancing our QRX009 topical rapamycin program towards clinical testing in early 2027.”
Company press release, Nov 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Shareholder vote Shareholders approved raising investors' beneficial ownership limits from 4.99% to up to 9.99% of outstanding ordinary shares, with 62,748,070 votes for and 8,304,240 abstentions. A second proposal to adjourn the meeting if needed also passed, with 62,748,630 votes for. Form 8-K · SEC filing
Nov 6, 2026 ·
Clinical trial Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with the primary endpoint at p=0.0087 and the key secondary at p=0.0070, and raised up to $50.0 million in a private placement with $30.8 million upfront. Cash was $33.2 million at September 30, 2026. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Financing Quoin Pharmaceuticals filed a shelf prospectus for up to $150,000,000 of ordinary shares as ADSs, warrants, subscription rights, debt securities and units, with terms to be set in later supplements. ADSs closed at $4.02 on October 23, 2026. Form 424B5 · SEC filing
Nov 4, 2026 ·
Financing Quoin Pharmaceuticals filed a prospectus supplement for an at-the-market offering of up to $11.0 million of ADSs through Leerink Partners, with a 3.0% commission. The ADSs closed at $3.93 on November 3, 2026. Form 424B5 · SEC filing
Nov 4, 2026 ·
Financing Quoin entered a sales agreement with Leerink Partners to sell American Depositary Shares at the market, under an effective Form S-3 shelf. Leerink will receive 3.0% of gross sale proceeds. No share count or price is stated. Form 8-K · SEC filing
Oct 28, 2026 ·
Financing Quoin Pharmaceuticals filed a shelf registration on Form S-3 to offer up to $150,000,000 of ordinary shares as ADSs, warrants, subscription rights, debt securities and units, in amounts, prices and terms to be set in future prospectus supplements. Form S-3 · SEC filing
Oct 20, 2026 ·
Clinical trial Published a peer-reviewed paper introducing QRX003 for Netherton Syndrome, with a pediatric case showing IGA improved from 4 to 0 by eight months and sustained near-clear skin over 21 months. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2/3 · Recruiting · Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome Registry primary completion date, not a results date
Dec 2026 · Phase 2/3 · Recruiting · Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Registry primary completion date, not a results date
Jan 2027 · Phase 2/3 · Recruiting · Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Registry primary completion date, not a results date
Dec 2025 · Phase 2/3 · Active Trial · Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
QNRX holds $33.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.5M/quarter from operations,
an estimated runway of 22.3 months at that rate (BioRadar estimate, not company guidance).
Share count 70,294,615 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full QNRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.